Zimmer Biomet: Paragon 28 debt drag masks an EPS inflection to $6-plus by FY2027

Stevie AI on Zimmer Biomet Holdings, Inc. (ZBH-USA | zimmerbiomet)

10/26/2026

Summary

Zimmer Biomet is a top-3 global orthopedic device maker with #1/#2 share positions in hips and knees, now layering the Paragon 28 foot-and-ankle acquisition onto its S.E.T. (Spine, Extremities, Trauma) segment to diversify away from a maturing, share-driven Knees business. The key structural insight is that FY2026 reported earnings understate the company's underlying earnings power: EPS of $3.92 is suppressed by elevated net interest expense (~$295M) tied to the debt-funded Paragon 28 deal and by lingering purchase-accounting drag on COGS, both of which unwind mechanically over the next three years as $1.6-1.9B of annual free cash flow retires net debt from $6.5B toward $4.3B by FY2029. Recent actuals show the transition pain clearly: FY2024 EPS of $4.43 fell to $3.55 in FY2025 despite revenue growing from $7.7B to $8.2B, as the Paragon 28 acquisition load and sales-force transformation costs compressed net income from $0.9B to $0.7B even as the top line grew. Management's own guidance update — raising FY2026 organic constant-currency growth to 2.25-3.25% and adjusted EPS to $8.47-8.59 on an adjusted basis, with free cash flow growing 9-11% — signals confidence that the worst of the transition disruption is behind the company, corroborated by Q2 2026 operating cash flow growth of 18% YoY. Applying a 14x forward P/E — a discount to Stryker's low-20s multiple reflecting ZBH's slower organic growth and ongoing integration risk, but above a trough multiple given the clear EPS recovery path — to FY2029 EPS of $8.64 yields a price target in the low-$120s, discounted back through the forecast years to reflect the FY2026-2027 earnings trough. This implies meaningful upside from the current $96.57 price, driven not by heroic growth assumptions but by debt normalization and margin stabilization that are already underwritten in company guidance.

Thesis

1. **Debt normalization is the primary EPS driver, not revenue growth.** The forecast shows net income roughly flat from FY2025's $0.7B to FY2026's $0.7B, then jumping to $1.0B in FY2027 — a 40%+ increase — primarily because net interest expense drag from the Paragon 28 acquisition abates as net debt falls from $6.5B to $5.8B and continues toward $4.3B by FY2029. EPS reflects this inflection even more sharply, rising from $3.92 in FY2026 to $6.22 in FY2027 (a 59% jump) and to $8.64 by FY2029, aided by the $1.0B buyback authorization reducing share count. This is a mechanical, financeable recovery rather than a speculative growth story, which makes it more underwritable for a value-oriented investor. 2. **Paragon 28 and S.E.T. diversify away from a structurally slower Knees franchise.** Knees softness has been a persistent drag, but the S.E.T. segment — now including Paragon 28's foot-and-ankle platform — is a genuine growth vector contributing roughly 110 basis points to FY2026 reported growth. Combined with Hips strength (the standout performer in recent quarters) and technology offerings like ROSA robotics and iodine-coated hip implants, ZBH's revenue mix is shifting toward higher-growth, less commoditized categories, even as blended organic growth stays in the 2.25-3.5% range. 3. **Margin stabilization is underwritten by management guidance, reducing forecast risk.** Gross margin guidance of ~71% for FY2026 (down only 120bps YoY) and operating margin down just slightly more than 50bps suggests the worst of the purchase-accounting and sales-force transformation cost drag is largely priced into FY2026 numbers already. If Stage 2 of the sales force transformation completes with

Risks

1. **U.S. sales force transformation execution risk.** Management is accelerating Stage 2 of a multi-year sales transformation it describes as having caused "less disruption than expected," but this is a self-assessment during an active rollout. Competitive poaching of reps by Stryker or J&J MedTech, lost surgeon relationships during rep turnover, and uneven regional performance could reignite the Knees softness that has already depressed FY2025 results, delaying the margin recovery embedded in FY2027-2029 estimates. 2. **Paragon 28 integration and purchase-accounting drag could persist longer than modeled.** The current EPS trough in FY2026 assumes purchase-accounting COGS drag normalizes on schedule. Any slippage in integration — manufacturing consolidation, distributor transitions, or incremental compliance costs — would push out the FY2027 EPS inflection to $6.22 that underpins much of the price target upside, and net debt paydown from $6.5B could stall if free cash flow disappoints. 3. **Pricing erosion and input cost inflation could compress margins further than guided.** Management's own guidance assumes flat to 100bps of pricing erosion in FY2026, with Q2 already showing an 80bps headwind. Elevated commodity/input costs tied to the broader inflationary backdrop are cited as an ongoing drag on the 71% gross margin target; a worse-than-expected pricing environment in Knees or Hips would directly undercut the operating margin stabilization thesis. 4. **China and emerging market weakness, plus FX volatility.** International headwinds — specifically China volume-based procurement/tender dynamics and broader emerging market softness — are flagged risks to the 2.25-3.25% organic growth guidance. A 50bps FX tailwind embedded in FY2026 guidance could reverse into a headwind (as already flagged for Q3), mechanically reducing reported growth and EPS below forecast. 5. **Competitive intensity from Stryker and J&J MedTech limits pricing power and share gains.** ZBH operates in a mature, essentially zero-sum recon market where share gains are difficult and come at the expense of larger, better-capitalized competitors. Robotics differentiation (ROSA, ROSA Shoulder) is necessary but not sufficient to reverse Knees softness if competitors out-innovate or out-spend ZBH on digital surgery platforms. 6. **Leverage amplifies downside if the EPS recovery is delayed.** With net debt at $6.5B in FY2026 against a ~$0.7B net income base, ZBH carries meaningful leverage. If the anticipated debt paydown trajectory to $4.3B by FY2029 is disrupted by weaker-than-expected free cash flow (currently guided at 9-11% growth), the interest expense drag that depresses FY2026 EPS could persist, delaying the thesis's core catalyst and pressuring the stock below the discounted price targets.

📈 Price Targets